Introduction
Collaborations are most fruitful when both parties bring complementary expertise but have a common/shared interest. For both of us, working in different buildings in University College London (UCL), the common interest was in identifying DNA variants that influence expression of key inflammatory cytokines, while the complementary interests were in cell and molecular biology of cytokines in systemic juvenile idiopathic arthritis (sJIA) and in molecular genetics and genetic epidemiology of coronary artery disease (CAD). At that time it was already clear that overexpression of IL-6 was likely to be central to the pathogenesis of the chronic systemic inflammation seen in young children with sJIA. Similarly, there had been growing recognition of the key role of inflammation in the development of atherosclerosis, with the landmark paper from the late Russell Ross in 1999 (1) .
The obvious place to look for functional variants affecting expression of IL6 was in the proximal promoter of the gene. These studies were carried out in a small cohort of normal healthy individuals by Daniel Fishman, a clinician studying for his PhD in the Woo laboratory (2). His findings set off a series of experiments to assess whether the identified variants affected gene expression, and he found that the variant in position -174 bp (subsequently designated as rs1800795) upstream of the transcriptional start site did in fact affect IL6 gene transcription. Furthermore, the common genotype in people of mixed European descent, GG, was significantly associated with sJIA cases when compared with the pool of controls from the Humphries laboratory. Subsequent analysis of the 5′-flanking region of IL6 by our groups at UCL identified further genetic variants up to 6 kb from the start of transcription that influence expression and are associated with serum levels (3) and constitutive expression (4). Most recently, we reported on a chromatin loop structure involving this -6-kb region that interacts directly with the proximal promoter region through OCT1 binding (5) . We are still working to identify the additional nuclear proteins involved in the exquisite control of this intriguing cytokine.
Genetic variants: a useful tool to probe the cause of inflammation
The discovery of a functional polymorphism in the IL6 gene led to a large number of candidate gene association studies in different inflammatory diseases. The problem with the SNP genetic association studies reported in the 1990s was that all of them were underpowered to detect the modest effects on a trait that would be expected for a common variant. As a consequence, all were tarred with the "false-positive" brush (6) . Indeed, some subsequent papers did not confirm the association with IL-6 levels in healthy subjects, but many did see this in patients undergoing an inflammatory stimulus such as after coronary artery bypass surgery (7) or an operation for periodontal gum disease (3). Diseases associated with raised IL-6 levels are numerous, including CAD and abdominal aortic aneurysms (AAA) as well as autoimmune diseases, such as systemic lupus erythematosis and rheumatoid arthritis. The number of inflammatory diseases with evidence of higher than normal IL-6 levels in serum or in tissues is growing (see Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI67221DS1). The accurate measurement of IL-6 in serum is complicated by the fact that IL-6 levels vary in a diurnal manner in the healthy individual, so the time of sampling would affect the final results. Unfortunately, none of the papers describing serum IL-6 levels provide data on time of collection or time to storage and length of storage.
In many cases, the increase in IL-6 levels is believed to be secondary to other inflammatory mediators such as IL-1 and TNF. The key question is whether there is a genetic predisposition in the disease under investigation to produce higher IL-6 levels, leading to a chronic proinflammatory state. In retrospect, it was remarkable that we observed a significant association of -174G>C with the serum IL-6 level in the healthy subjects, and the "winner's curse" may explain the smaller effects reported subsequently. However, the identification of a functional variant, which because of disequilibrium marks a functional haplotype of IL6 promoter variants, has allowed this SNP to be used as a genetic instrument to probe the causality of higher IL-6 levels in many different disease states, an approach known as Mendelian randomization (8) . Further, this variant has been used to probe the influence of elevated IL-6 levels in many disease-state meta-analyses, some of which include more than 100,000 subjects (see Supplemental Table  1 ), ensuring the statistical robustness of the associations.
Clinical relevance of IL6 polymorphisms
Confirmation of disease association of the IL6 gene with sJIA was obtained in a study of families from the United Kingdom and America that used the transmission disequilibrium test (9) . Since then, multiple genes have been associated with sJIA, likely reflecting multiple pathogenetic factors leading to the same clinical syndrome (reviewed in ref. 10). Currently, an international consortium is carrying out a whole-genome scan, but even with worldwide collection of genotypes from people of mixed European origins, the numbers still fall short of that required for a conventional, statistically acceptable result. It is possible that with the availability of exome sequencing and next-generation whole-genome sequencing the genetic architecture of sJIA may be unravelled within the next few years.
The discovery of the association of IL6 with sJIA lent considerable weight to the hypothesis that IL-6 is central to the pathology of this disease and led to the clinical trial of an IL-6 receptor (IL-6R) monoclonal antibody (see Figure 1) to block IL-6 classical and trans-signaling in an orphan disease such as sJIA. Despite the "weak" genetic association, this antibody (tocilizumab) has proven to have remarkable efficacy in this disease in a proof-of-principle phase I/II study with a single dose and in a separate dose-escalation study (11, 12) . The subsequent multinational phase III double-blind placebo-controlled trial achieved the primary outcome in 85% of treated cases compared with 24% in the placebo group at week 12, and 80% of treated patients showed 70% improvement at week 52 (13) . In rheumatoid arthritis, the antibody's efficacy is around 60% to 65%. Tocilizumab is now approved as a second-line treatment agent for sJIA by the FDA and European Medicines Agency. The finding that common IL6R SNPs that are associated with low levels of systemic inflammation are also strongly predictive of CAD (14) and AAA (15) suggests that agents such as tocilizumab may be beneficial for treatment of these diseases as well. 
